natgillin/translations-raw huggingface dataset:
Raloxifene (n = 317) was compared with continuous combined (n = 110) hormone replacement therapy (HRT) or cyclic (n = 205) HRT patients in some clinical trials. 
Raloksifen (n = 317) so v nekaterih kliničnih preskušanjih primerjali s kontinuirano kombinirano (n = 110) hormonsko nadomestno terapijo (HRT) ali s ciklično HRT (n = 205).
- If you are receiving oral oestrogen therapy. 
- Če prejemateperoralno estrogensko terapijo.
In addition, in a study with 2.5 x the recommended daily dose of raloxifene there was no evidence of endometrial proliferation and no increase in uterine volume. 
Poleg tega v raziskavi z 2,5-kratnim priporočenim dnevnim odmerkom raloksifena ni bilo nobenih znakov proliferacije endometrija in niso ugotovili povečanja prostornine maternice.
Until safety and efficacy have been evaluated further in patients with hepatic insufficiency, the use of raloxifene is not recommended in this patient population. 
Dokler varnost in učinkovitost zdravila pri bolnicah z jetrno insuficienco ne bosta bolje raziskani, ne priporočamo uporabe raloksifena pri tej vrsti bolnic.
Your doctor will tell you how long you should continue to take Raloxifene Teva. 
Zdravnik vam bo povedal, kako dolgo naj bi jemali zdravilo Raloksifen Teva.
• Increased risk of blood clots in the lungs (pulmonary embolism). 
• povečano tveganje krvnih strdkov v pljučih (pljučna embolija)
No data are available on the concomitant use of raloxifene and agents used in the treatment of early or advanced breast cancer. 
Tako ni podatkov o sočasnem zdravljenju z raloksifenom in drugimi zdravili, ki se uporabljajo za zdravljenje zgodnjega ali napredovalega raka dojke.
This finding should be considered when prescribing raloxifene for postmenopausal women with a history of stroke or other significant stroke risk factors, such as transient ischemic attack or atrial fibrillation. 
To ugotovitev je potrebno upoštevati pri predpisovanju raloksifena postmenopavzalnim ženskam z anamnezo možganske kapi ali drugih značilnih dejavnikov tveganja za možgansko kap, kot so na primer tranzitorna ishemična ataka ali atrijska fibrilacija.
It is important that you continue taking Raloxifene Teva for as long as your doctor prescribes the medicine. 
Pomembno je, da nadaljujete z jemanjem zdravila Raloksifen Teva toliko časa kot vam je predpisal zdravnik.
• Blood clot in an artery (for example stroke, including an increased risk of dying from stroke) 
• krvni strdek v arteriji (na primer možganska kap, vključno s povečanim tveganjem za smrt zaradi možganske kapi)
Limited clinical data suggest that in patients with a history of oral oestrogen-induced hypertriglyceridemia (> 5.6 mmol/l), raloxifene may be associated with a marked increase in serum triglycerides. 
Omejeno število kliničnih podatkov kaže, da je pri bolnicah, ki so že imele s peroralnimi estrogeni povzročeno hipertrigliceridemijo (> 5,6 mmol/l), raloksifen lahko povezan z znatno povečanimi serumskimi trigliceridi.
Raloxifene Teva belongs to a group of non-hormonal medicines called selective oestrogen receptor modulators (SERMs). 
Raloksifen Teva sodi v skupino nehormonskih zdravil, imenovano selektivni modulatorji estrogenskega receptorja (SERM).
Raloxifene has no or negligible influence on the ability to drive and use machines. 
Raloksifen nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje ali upravljanja s stroji.
The hazard ratio for all VTE events in the RUTH study was HR = 1.44, (1.06-1.95). 
Razmerje tveganja za vse venske tromboembolične zaplete v študiji RUTH je bilo HR = 1,44, (1,66-1,95).
However, if you have taken oestrogen in the past and had extreme elevations in triglycerides, you should talk to your doctor before taking Raloxifene Teva. 
Če ste v preteklosti že jemali estrogene in ob tem imeli močno povišane vrednosti trigliceridov, se pred jemanjem zdravila Raloksifen Teva pogovorite s svojim zdravnikom.
Raloxifene has no effect on the risk of ER negative breast cancers. 
Raloksifen ne vpliva na tveganje za ER negativne vrste raka dojke.
Pharmaco-therapeutic group: Selective oestrogen receptor modulator. 
Farmakoterapevtska skupina: selektivni modulatorji estrogenskega receptorja.
Patients with renal impairment: 
Bolniki z okvaro ledvic:
If you take more Raloxifene Teva than you should Tell your doctor or pharmacist. 
Če ste vzeli večji odmerek zdravila Raloksifen Teva, kot bi smeli Obvestite zdravnika ali farmacevta.
If you forget to take Raloxifene Teva Take a tablet as soon as you remember and then continue as before. 
Vzemite eno tableto takoj, ko se spomnite, in potem nadaljujte enako kot prej.
What Raloxifene Teva is and what it is used for 
Kaj je zdravilo Raloksifen Teva in za kaj ga uporabljamo
Three trials included 1,764 postmenopausal women who were treated with raloxifene and calcium or calcium supplemented placebo. 
1.764 žensk po menopavzi, ki so bile zdravljene z raloksifenom in dodatki kalcija ali s placebom in dodatki kalcija.
As safety information regarding co-administration of raloxifene with systemic oestrogens, is limited, such use is not recommended. 
Ker so informacije v zvezi z varnostjo ob sočasnem jemanju raloksifena s sistemskimi estrogeni omejene, takšne kombinacije zdravljenja ne priporočamo.
Raloxifene should not be used in patients with severe renal impairment (see section 4.3). 
Raloksifen se ne sme uporabljati pri bolnikih s hudo okvaro ledvic (glejte poglavje 4.3).
Raloxifene reduced the incidence of clinical vertebral fractures by 35 % compared with placebo (HR 0.65, CI 0.47 0.89). 
Raloksifen je zmanjšal incidenco kliničnih zlomov vretenc za 35 % v primerjavi s placebom (HR 0,65, CI 0,47-0,89).
Recent data suggests that the oestrogen receptor can regulate gene expression by at least two distinct pathways which are ligand-, tissue-, and/or gene-specific. 
Novejši podatki kažejo, da lahko estrogenski receptor regulira gensko ekspresijo po vsaj dveh različnih poteh, ki sta specifični za ligand,
Although it may have no symptoms at first, osteoporosis makes you more likely to break bones, especially in your spine, hips and wrists and may cause back pain, loss of height and a curved back. 
Četudi morda sprva ni nobenih simptomov, se zaradi osteoporoze poveča verjetnost zlomov kosti, še posebej v hrbtenici, kolku in zapestju, lahko pa povzroči tudi bolečine v hrbtu,
Forty five women with osteoporosis or 15 women with osteoporosis with an existing fracture would need to be treated with raloxifene for 3 years to prevent one or more vertebral fractures. 
Da bi preprečili enega ali več zlomov vretenc, bi bilo treba z raloksifenom zdraviti petinštirideset žensk z osteoporozo ali 15 žensk z osteoporozo in obstoječim zlomom 3 leta.
Raloxifene is not effective in reducing vasodilatation (hot flushes), or other symptoms of the menopause associated with oestrogen deficiency. 
Raloksifen ni učinkovito zdravilo za zmanjševanje vazodilatacije (navalov vročine) ali drugih simptomov menopavze, ki so povezani s pomanjkanjem estrogena.
Raloxifene modestly increases hormone-binding globulin concentrations, including sex steroid binding globulins (SHBG), thyroxine binding globulin (TBG), and corticosteroid binding globulin (CBG), with corresponding increases in total hormone concentrations. 
Raloksifen zmerno poveča koncentracije globulinov, na katere se vežejo hormoni, vključno z globulini, na katere se vežejo steroidni spolni hormoni (SHBG), globulini, na katere se veže tiroksin (TBG), in globulini za vezavo kortikosteroidov (CBG), kar povzroči ustrezno povečanje skupne koncentracije hormonov.
In children, symptoms of accidental overdose included ataxia, dizziness, vomiting, rash, diarrhea, tremor, and flushing, and elevation in alkaline phosphatase. 
Simptomi naključnega prevelikega odmerjanja pri otrocih so vključevali ataksijo, omotico, bruhanje, izpuščaj, drisko, tresenje in rdečico ter povišanje alkalne fosfataze.
Presystemic glucuronidation is exten sive. 
Predsistemska glukuronidacija je obsežna.
When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1). 
Ko se zdravnik pri posamezni ženski po menopavzi odloča med raloksifen ali drugimi oblikami zdravljenja, vključno z estrogeni, mora pri tem upoštevati simptome menopavze pri njej in učinke zdravila na tkivo maternice in dojke ter pretehtati tveganja in koristi za srčnožilna obolenja (glejte poglavje 5.1).
The clinically most important adverse reactions reported in postmenopausal women treated with Raloxifen were venous thromboembolic events (see section 4.4), which occurred in less than 1% of treated patients. 
Klinično najpomembnejši neželeni učinki, o katerih so poročali pri postmenopavzalnih ženskah, ki so se zdravile z zdravilom Raloksifen Teva, so bili venski tromboembolični dogodki (glejte poglavje 4.4), ki so se pojavili pri manj kot 1 % zdravljenih bolnicah.
Raloxifene Teva is for use only by postmenopausal women and must not be taken by women who could still have a baby. 
Zdravilo Raloksifen Teva je namenjeno le ženskam po menopavzi in ga ne smejo jemati ženske, ki bi še lahko zanosile.
• Increased risk of blood clots in the eyes (retinal vein thrombosis). 
• povečano tveganje krvnih strdkov v očeh (tromboza retinalnih ven)
Raloxifene Teva 60 mg is available in pack sizes of 14, 28 and 84 film-coated tablets. 
Zdravilo Raloksifen Teva 60 mg je na voljo v velikostih pakiranj s po 14, 28 in 84 filmsko obloženih tablet.
Do not take Raloxifene Teva if you are breast-feeding as it might be excreted in mother's milk. 
Ne jemljite zdravila Raloksifen Teva če dojite, saj lahko zdravilo prehaja v materino mleko.
Likewise, raloxifene is indicated for the treatment of osteoporosis or established osteoporosis in women with BMD of the spine 2.5 SD below the mean value of a normal young population and/or with vertebral fractures, irrespective of BMD. 
Podobno velja, da je raloksifen indiciran za zdravljenje osteoporoze ali ugotovljene osteoporoze pri ženskah, ki imajo vrednosti BMD za hrbtenico za 2,5 SD nižje od srednje vrednosti zdrave mlade populacije in/ali imajo zlome vretenc, ne glede na vrednosti BMD.
Superficial vein thrombophlebitis occurred in a frequency of less than 1 %. 
Tromboflebitis povrhnjih ven se je pojavljal s pogostnostjo, manjšo od 1 %.
Compared to placebo there was no increased use in raloxifene treated patients. 
V primerjavi s placebom ni bila opažena povečana uporaba pri bolnicah, zdravljenih z raloksifenom.
Raloxifene Teva can treat or prevent your osteoporosis only if you continue to take the tablets. 
Zdravilo Raloksifen Teva lahko zdravi in preprečuje osteoporozo samo, če nadaljujete z jemanjem tablet.
for the spine 37 % decreased and 63 % increased; and for the total hip 29 % decreased and 71 % increased. 
naslednji: za hrbtenico so pri 37 % preiskovank ugotovili zmanjšanje in pri 63 % povečanje BMD; za celoten kolk so pri 29 % ugotovili zmanjšanje in pri 71 % povečanje BMD.
The incidence of stroke mortality was 2.2 per 1,000 women per year for raloxifene versus 1.5 per 1,000 women per year for placebo (see section 4.4). 
Pogostnost smrtnosti zaradi možganske kapi je bila 2,2 na 1000 žensk na leto za raloksifen proti 1,5 na 1000 žensk na leto za placebo (glejte poglavje 4.4).
th year, patients were permitted the concomitant use of bisphosphonates, calcitonin and fluorides and all patients in this study received calcium and vitamin D supplementation. 
Od četrtega do osmega leta zdravljenja so bolnicam dovolili sočasno jemanje difosfonatov, kalcitonina in fluoridov in vse bolnice iz te raziskave so jemale dodatke kalcija in vitamina D.
Across all placebo-controlled trials, raloxifene was indistinguishable from placebo with regard to frequency and severity of breast symptoms (no swelling, tenderness and breast pain). 
V vseh s placebom nadzorovanih preskušanjih vpliva zdravljenja z raloksifenom ni bilo mogoče razlikovati od vpliva placeba, kar zadeva pogostnost in stopnjo simptomov v zvezi z dojkami (brez nabrekanja, občutljivosti in bolečin v dojkah).
In patients with moderate and mild renal impairment, raloxifene should be used with caution. 
Pri bolnikih z blago do zmerno okvaro ledvic je potrebna previdnost.
Based on these risk factors, prevention of osteoporosis with raloxifene is indicated for women within ten years of menopause, with BMD of the spine between 1.0 and 2.5 SD below the mean value of a normal young population, taking into account their high lifetime risk for osteoporotic fractures. 
Glede na naštete dejavnike tveganja je preventiva osteoporoze z raloksifenom indicirana v obdobju desetih let po nastopu menopavze pri tistih ženskah, ki imajo vrednosti BMD za hrbtenico za 1,0 do 2,5 SD nižje od srednje vrednosti zdrave mlade populacije, upoštevajoč, da obstaja pri teh ženskah veliko tveganje za zlome kosti zaradi osteoporoze skozi vso nadaljnjo življenjsko dobo.
In vitro, raloxifene did not interact with the binding of warfarin, phenytoin, or tamoxifen. 
In vitro, raloksifen ni vplival na vezavo varfarina, fenitoina ali tamoksifena.
Compared to placebo, raloxifene was not associated with spotting or bleeding or endometrial hyperplasia. 
primerjavi s placebom uporaba raloksifena ni pokazala povezave s krvavim izcedkom, krvavitvami ali hiperplazijo endometrija.
Raloxifene should be discontinued in the event of an illness or a condition leading to a prolonged period of immobilisation. 
Raloksifen je treba prenehati jemati pri kateri koli bolezni ali motnji, ki vodi do daljše imobilizacije bolnice.
- If you have liver problems, as there is insufficient experience in people with liver problems. 
- Če imate težave z jetri, saj ni dovolj izkušenj z bolniki z jetrnimi boleznimi.
Polydextrose (E1200) Titanium dioxide (E171) Hypromellose (E464) Macrogol 4000 
Filmska obloga tablete: polidekstroza (E1200) titanov dioksid (E171) hipromeloza (E464) makrogol 4000
What Raloxifene Teva is and what it is used for What you need to know before you take Raloxifene Teva How to take Raloxifene Teva Possible side effects 
Kaj je zdravilo Raloksifen Teva in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Raloksifen Teva Kako jemati zdravilo Raloksifen Teva
The following convention has been used for the classification of the adverse reactions: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) very rare (< 1/10,000), not known (cannot be estimated from the available data). 
(≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki
The incidence of stroke mortality was 1.5 per 1000 women per year for placebo versus 2.2 per 1000 women per year for raloxifene. 
Incidenca smrtnosti zaradi možganske kapi je bila 1,5 na 1000 žensk na leto za placebo proti 2,2 na 1000 žensk na leto za raloksifen.
Do not use this medicine after the expiry date which is stated on the outer carton or foil after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na zunanji škatli ali foliji, poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
In a study of 10,101 postmenopausal women with documented coronary heart disease or at increased risk for coronary events (RUTH) , the occurrence of vasodilatation (hot flushes) was 7.8 % in the raloxifene-treated patients and 4.7 % in the placebo-treated patients. 
V študiji 10.101 postmenopavzalnih žensk z dokazano koronarno srčno boleznijo ali s povečanim tveganjem za koronarne dogodke (RUTH), je bila pojavnost vazodilatacije (vročinskih oblivov) pri bolnicah zdravljenih z raloksifenom 7,8 % in 4,7 % pri bolnicah, ki so jemale placebo.
• Skin around the vein is red and painful (superficial vein thrombophlebitis). 
• rdeča in boleča koža v okolici vene (površinski venski tromoflebitis)
The frequencies for postmarketing reports were calculated from placebo-controlled clinical trials (comprising a total of 15,234 patients, 7,601 on raloxifene 60 mg and 7,633 on placebo) in postmenopausal women with osteoporosis, or established coronary heart disease (CHD) or increased risk for CHD, without comparison to the frequencies of adverse events in the placebo assignment groups. 
Pogostnosti za poročila v obdobju trženja so bile preračunane iz s placebom nadzorovanih kliničnih preskušanj (v katera je bilo vključenih 15.234 bolnic, 7.601 jih je prejemalo 60 mg raloksifena in 7.633 jih je prejemalo placebo) pri postmenopavzalnih ženskah z osteoporozo, z ugotovljeno koronarno boleznijo srca (CHD) ali s povečanim tveganjem za CHD, brez primerjave s pogostnostmi neželenih učinkov v placebo skupini.
Other medicines and Raloxifene Teva 
Druga zdravila in zdravilo Raloksifen Teva
The time to reach average maximum plasma concentration and bioavailability are functions of systemic interconversion and enterohepatic cycling of raloxifene and its glucuronide metabolites. 
da raloksifen doseže povprečne vrednosti maksimalne plazemske koncentracije in biološke uporabnosti, je odvisen od sistemske interkonverzije ter enterohepatične cirkulacije raloksifena in njegovih glukuronidnih presnovkov.
- If you have liver disease (examples of liver disease include cirrhosis, mild hepatic impairment or cholestatic jaundice). 
- Če imate bolezen jeter (jetrne bolezni so na primer ciroza, blaga okvara jeter ali holestatska zlatenica).
• Hot flushes (vasodilatation). 
• vročinski oblivi (vazodilatacija)
Raloxifene produced significant increases in bone density of hip and spine as well as total body mineral mass compared to placebo. 
Raloksifen je povzročil značilno povečanje kostne gostote v kolku in hrbtenici, pa tudi značilno povečanje celotne kostne mineralne mase v telesu v primerjavi s placebom.
Serum total bilirubin, gamma-glutamyl transferase, alkaline phosphatase, ALT and AST should be closely monitored during treatment if elevated values are observed. 
Med zdravljenjem je treba skrbno spremljati vrednosti serumskih koncentracij celokupnega bilirubina, gama-glutamil transferaze, alkalne fosfataze, ALT in AST, če pri bolnici ugotovimo povišane vrednosti.
Frequently co-administered medicinal products included: paracetamol, non-steroidal anti-inflammatory drugs (such as acetylsalicylic acid, ibuprofen, and naproxen), oral antibiotics, H1 antagonists, H2 antagonists, and benzodiazepines. 
nesteroidna protivnetna zdravila (kakor so acetilsalicilna kislina, ibuprofen in naproksen), peroralni antibiotiki, antagonisti H1 receptorjev, antagonisti H2 receptorjev in benzodiazepini.
A reduction in the risk of hip fractures has not been shown. 
Raziskave niso pokazale zmanjšanja tveganja za zlom kolka.
Raloxifene Teva lowers total cholesterol and LDL ("bad") cholesterol. 
Zdravilo Raloksifen Teva znižuje vrednost celokupnega holesterola in LDL ('slabega') holesterola.
During an average follow-up of 5.6 years, 59 (1.2%) raloxifene-treated women died due to a stroke compared to 39 (0.8%) placebo-treated women. 
Med povprečnim spremljanjem 5,6 let je 59 (1,2 %) žensk, ki so se zdravile z raloksifenom in 39 (0,8 %) žensk, ki so se zdravile s placebom, umrlo zaradi možganske kapi.
Therefore, raloxifene should be used for osteoporosis treatment and prevention only after the treatment of breast cancer, including adjuvant therapy, has been completed. 
Raloksifen se za zdravljenje in preprečevanje osteoporoze lahko uporablja le po zaključenem zdravljenju raka dojke, vključno z vso spremljajočo terapijo.
Tablet coating: polydextrose (E1200), titanium dioxide (E171), hypromellose (E464) and macrogol 4000. 
Filmska obloga tablete: polidekstroza (E1200), titanov dioksid (E171), hipromeloza (E464) in makrogol 4000.
Raloxifene should not be used in patients with hepatic impairment (see section 4.3 and 4.4). 
Bolniki z okvaro jeter: Raloksifen se ne sme uporabljati pri bolnikih z okvaro jeter (glejte poglavji 4.3 in 4.4).
Across all placebo-controlled clinical trials of raloxifene in osteoporosis, venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis occurred at a frequency of approximately 0.8 % or 3.22 cases per 1,000 patient years. 
V vseh kliničnih preskušanjih raloksifena pri osteoporozi, nadzorovanih s placebom, so se venski tromboembolični zapleti, vključno s trombozo globokih ven, pljučnimi embolijami in trombozo retinalnih ven, pojavljali v približno 0,8 % ali 3,22 primerih na 1.000 bolnic-let.
Clinical trials showed that a 60 mg daily dose of raloxifene significantly decreased total cholesterol (3 to 6 %), and LDL cholesterol (4 to 10 %). 
b) Vplivi na presnovo lipidov in srčnožilno tveganje Klinične raziskave so pokazale, da dnevni odmerek 60 mg raloksifena značilno zniža vrednosti skupnega holesterola (3 do 6 %) in LDL holesterola (4 do 10 %).
If you take more Raloxifene Teva than you should you could have leg cramps and dizziness. 
Če ste vzeli večji odmerek zdravila Raloksifen Teva, kot bi smeli, se pri vas lahko pojavijo krči v nogah ali omotica.
The safety of raloxifene in patients with breast cancer has not been adequately studied. 
Zadostnih študij o varnosti raloksifena pri bolnicah z rakom dojke ni.
Raloxifene therapy for 8 years did not significantly affect the risk of cardiovascular events in patients enrolled in the osteoporosis treatment study. 
Osemletno zdravljenje z raloksifenom pri bolnicah, vključenih v študijo zdravljenja osteoporoze, ni značilno vplivalo na tveganje za srčnožilne dogodke.
Do not take Raloxifene Teva - If you are allergic to raloxifene or any of the other ingredients of this medicine (listed in section 
- Če ste alergični na raloksifen ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
- If you are suffering from breast cancer, as there is insufficient experience of Raloxifene Teva use in women with this disease. 
- Če imate raka dojke, ker ni zadosti izkušenj z uporabo zdravila Raloksifen Teva pri ženskah s to boleznijo.
Nervous system disorders Common: Headache, including migraine a 
Bolezni živčevja Pogosti: glavobol, vključno z migrenoa
This was peripheral oedema, which occurred in the prevention population at an incidence of 3.1 % for raloxifene and 1.9 % for placebo; and in the treatment population occurred at an incidence of 7.1 % for raloxifene and 6.1 % for placebo. 
To je bil periferni edem, ki se je v skupini, pri kateri so raloksifen uporabljali za preventivo, pojavljal z incidenco 3,1 % za raloksifen in 1,9 % za placebo ter v skupini, pri kateri so raloksifen uporabljali za zdravljenje, z incidenco 7,1 % za raloksifen in 6,1 % za placebo.
The two most frequent diagnoses associated with uterine bleeding during raloxifene treatment were endometrial atrophy and benign endometrial polyps. 
povezani s krvavitvijo iz maternice med zdravljenjem z raloksifenom, sta bili atrofija endometrija in benigni polipi endometrija.
Flu syndrome was reported by 16.2 % of raloxifene treated patients and 14.0 % of placebo treated patients. 
O sindromu gripe so poročali pri 16,2 % bolnic, zdravljenih z raloksifenom, in pri 14,0 % bolnic, ki so jemale placebo.
Raloxifene undergoes extensive first pass metabolism to the glucuronide conjugates: raloxifene-4'-glucuronide, raloxifene-6-glucuronide, and raloxifene-6, 4′-diglucuronide . 
Raloksifen se že pri prvem prehodu skozi jetra v veliki meri presnovi v glukuronidne konjugate: raloksifen-4'-glukuronid, raloksifen-6-glukuronid in raloksifen-6,4'-diglukuronid.
Raloxifene should not be used in children of any age. 
Zdravilo Raloksifen Teva se ne sme uporabljati pri otrocih katere koli starosti.
Raloxifene Teva does not treat postmenopausal symptoms, such as hot flushes. 
Zdravilo Raloksifen Teva ne zdravi postmenopavzalnih simptomov, kot so vročinski oblivi.
EU/1/10/627/003 84 film coated tablets 
EU/1/10/627/001 14 filmsko obloženih tablet EU/1/10/627/002 28 filmsko obloženih tablet EU/1/10/627/003 84 filmsko obloženih tablet
In the osteoporosis treatment study, significantly fewer raloxifene-treated patients required initiation of hypolipidaemic therapy compared to placebo. 
V študiji zdravljenja osteoporoze je bila pri bolnicah, zdravljenih z raloksifenom uvedba hipolipemične terapije potrebna pri značilno manjšem številu v primerjavi s placebom